Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorFumagalli, Andrea
dc.contributor.authorTrivedi, Dakshat
dc.contributor.authorRamos , Rafel
dc.contributor.authorMartín-García, Elena
dc.contributor.authorMaldonado, Rafael
dc.contributor.authorFernández-Real, Jose Manuel
dc.contributor.authorCastells-Nobau, Anna
dc.contributor.authorGarre-Olmo, Josep
dc.contributor.authorPuig, Josep
dc.contributor.authorRamió-Torrentà, Lluís
dc.contributor.authorMAYNERIS-PERXACHS, JORDI
dc.date.accessioned2025-08-04T06:51:55Z
dc.date.available2025-08-04T06:51:55Z
dc.date.issued2025-02-05
dc.identifier.citationFumagalli A, Castells-Nobau A, Trivedi D, Garre-Olmo J, Puig J, Ramos R, et al. Archaea methanogens are associated with cognitive performance through the shaping of gut microbiota, butyrate and histidine metabolism. Gut Microbes. 2025 Dec;17(1):2455506.
dc.identifier.issn1949-0984
dc.identifier.urihttp://hdl.handle.net/11351/13466
dc.descriptionArchaea; Methanogens; Gut microbiota; Cognitive performance
dc.description.abstractThe relationship between bacteria, cognitive function and obesity is well established, yet the role of archaeal species remains underexplored. We used shotgun metagenomics and neuropsychological tests to identify microbial species associated with cognition in a discovery cohort (IRONMET, n = 125). Interestingly, methanogen archaeas exhibited the strongest positive associations with cognition, particularly Methanobrevibacter smithii (M. smithii). Stratifying individuals by median-centered log ratios (CLR) of M. smithii (low and high M. smithii groups: LMs and HMs) revealed that HMs exhibited better cognition and distinct gut bacterial profiles (PERMANOVA p = 0.001), characterized by increased levels of Verrucomicrobia, Synergistetes and Lentisphaerae species and reduced levels of Bacteroidetes and Proteobacteria. Several of these species were linked to the cognitive test scores. These findings were replicated in a large-scale validation cohort (Aging Imageomics, n = 942). Functional analyses revealed an enrichment of energy, butyrate, and bile acid metabolism in HMs in both cohorts. Global plasma metabolomics by CIL LC-MS in IRONMET identified an enrichment of methylhistidine, phenylacetate, alpha-linolenic and linoleic acid, and secondary bile acid metabolism associated with increased levels of 3-methylhistidine, phenylacetylgluamine, adrenic acid, and isolithocholic acid in the HMs group. Phenylacetate and linoleic acid metabolism also emerged in the Aging Imageomics cohort performing untargeted HPLC-ESI-MS/MS metabolic profiling, while a targeted bile acid profiling identified again isolithocholic acid as one of the most significant bile acid increased in the HMs. 3-Methylhistidine levels were also associated with intense physical activity in a second validation cohort (IRONMET-CGM, n = 116). Finally, FMT from HMs donors improved cognitive flexibility, reduced weight, and altered SCFAs, histidine-, linoleic acid- and phenylalanine-related metabolites in the dorsal striatum of recipient mice. M. smithii seems to interact with the bacterial ecosystem affecting butyrate, histidine, phenylalanine, and linoleic acid metabolism with a positive impact on cognition, constituting a promising therapeutic target to enhance cognitive performance, especially in subjects with obesity.
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofseriesGut Microbes;17(1)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectArqueus - Metabolisme
dc.subjectIntestins - Microbiologia
dc.subjectCognició
dc.subject.meshArchaea
dc.subject.mesh/metabolism
dc.subject.meshGastrointestinal Microbiome
dc.subject.meshCognition
dc.subject.mesh/physiology
dc.subject.meshNervous System Physiological Phenomena
dc.titleArchaea methanogens are associated with cognitive performance through the shaping of gut microbiota, butyrate and histidine metabolism
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1080/19490976.2025.2455506
dc.subject.decsArchaea
dc.subject.decs/metabolismo
dc.subject.decsmicrobiota intestinal
dc.subject.decscognición
dc.subject.decs/fisiología
dc.subject.decsfenómenos fisiológicos del sistema nervioso
dc.relation.publishversionhttps://www.doi.org/10.1080/19490976.2025.2455506
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Fumagalli A, Castells-Nobau A] a Servei de Diabetis, Endocrinologia i Nutrició, Hospital Universitari Dr. Josep Trueta, Girona, Spain. Grup de Recerca en Nutrició, Eumetabolisme i Salut, Institut d’Investigació Biomèdica de Girona Dr. Josep (IDIBGI), Salt, Spain. Grup de Recerca en Medicina i Biologia Integrativa de Sistemes, Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Salt, Spain. Centro de Investigación Biomédica en Red en Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. [Trivedi D] School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. [Garre-Olmo J] Programa Serra Húnter del Departament d’Infermeria, Universitat de Girona, Girona, Spain. [Puig J] Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, Girona, Spain. Unitat de Recerca de l’Institut de Diagnòstic per la Imatge (IDI), Parc Sanitari Pere Virgili, Barcelona, Spain. Imatge Mèdica, Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Salt, Spain. Servei de Radiologia, Institut de Diagnòstic per la Imatge (IDI), Hospital Universitari Dr. Josep Trueta, Girona, Spain. [Ramos R] Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, Girona, Spain. Grup d’Investigació en Salut Vascular de Girona (ISV-Girona), Institut Universitari per a la Recerca en Atenció Primària Jordi Gol (IDIAPJGol), Girona, Spain. Red de Investigación en Cronicidad, Atención Primaria y Prevención y Promoción de la Salud (RICAPPS), Instituto de Salud Carlos III (ISCIII), Girona, Spain. Grup de Recerca en Investigació en Salut Vascular, Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Salt, Spain. [Ramió-Torrentà L] Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, Girona, Spain. Unitat de Neuroimmunologia i Esclerosi Múltiple Territorial Girona (UNIEMTG), Servei de Neurologia, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain. Grup de Recerca en Neurodegeneració i Neuroinflamació, Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Salt, Spain. [Martin-Garcia E, Maldonado R] Grup de Recerca del Laboratori de Neurofarmacologia (Neurophar), Departament de Ciències Experimentals i de la Salut (DCEXS), Universitat Pompeu Fabra (UPF), Barcelona, Spain. Hospital del Mar Research Institute (IMIM), Hospital del Mar, Barcelona, Spain. [Fernández-Real JM] Servei de Diabetis, Endocrinologia i Nutrició, Hospital Universitari Dr. Josep Trueta, Girona, Spain. Grup de Recerca en Nutrició, Eumetabolisme i Salut, Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Salt, Spain. Centro de Investigación Biomédica en Red en Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. [Mayneris-Perxachs, J] Servei de Diabetis, Endocrinologia i Nutrició, Hospital Universitari Dr. Josep Trueta, Girona, Spain. Grup de Recerca en Medicina i Biologia Integrativa de Sistemes, Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Salt, Spain. Centro de Investigación Biomédica en Red en Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
dc.identifier.pmid39910065
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record